To determine if breast cancer patients have T cell repertoires that recognize these MUC1 peptides, we screened 23 HLA-A*0201 breast cancer patients regardless of their stage, ER/PR and HER2 status with four selected peptides (P1, P3, P4, P15). Here, ERBB2 is linked to breast carcinoma.